Effects of Short-Term Exposure to High-Dose Inhaled Corticosteroids on Appetite, Dietary Intake, Leptin Levels, and Body Weight in Adults with Asthma—A Prospective Pilot Study

<b>Background:</b> Inhaled corticosteroids (ICSs) are a cornerstone in asthma management, particularly during exacerbations, when high doses are often prescribed. However, patient concerns about potential side effects such as increased appetite, weight gain, and metabolic disturbances may reduce adherence, compromising treatment outcomes. While oral corticosteroids (OCSs) are well known to induce such effects, the metabolic impact of short-term high-dose ICSs remains poorly studied. <b>Objective:</b> This prospective pilot study aimed to assess whether a 14-day course of high-dose ICSs in adults with stable asthma induces changes in appetite, dietary intake, leptin levels, or body weight. <b>Methods:</b> Thirty-five adults (19 males, 16 females; mean age 48.7 ± 15.1 years) with stable mild asthma received ≥400 µg/day extrafine beclomethasone dipropionate/formoterol via pressurized metered-dose inhaler for 14 days. Participants underwent assessments at baseline and after 14 days, including body weight, BMI, fasting serum leptin levels, dietary intake (evaluated using 24 h dietary recalls), and appetite (measured via a visual analogue scale). <b>Results:</b> No significant changes were observed in body weight (mean change: -0.38 kg; 95% CI: -0.81 to 0.05; <i>p</i> = 0.083) or BMI (<i>p</i> = 0.912) following high-dose ICS use. Similarly, serum leptin levels (mean change: 0.13 ng/mL; 95% CI: -3.47 to 3.72; <i>p</i> = 0.945), subjective appetite scores (mean change: -4.93 mm; 95% CI: -13.64 to 3.79; <i>p</i> = 0.267), and dietary energy intake (mean change: +255 kJ/day; 95% CI: -380 to 891; <i>p</i> = 0.431) did not differ significantly post-intervention. <b>Conclusions:</b> Short-term high-dose ICS therapy in adults with mild asthma may not significantly affect appetite, dietary intake, leptin levels, or body weight. These findings support the metabolic safety of short-term high-dose ICSs and may help alleviate patient concerns, improving adherence during exacerbation management.